Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 5,457 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor Malignancies, Cancer Clear all
Completed Phase 1 Interventional

A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

NCT00117013
View directory record Official record
Conditions
Neoplasms
Interventions
Fluorine-19-Fluoroded Xyglucose, Topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

NCT00095459
View directory record Official record
Conditions
Neoplasms
Interventions
Bevacizumab, BAY 43-9006
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

A Study of NM-3 Administered Orally in Patients With Advanced Solid Tumors.

NCT00046696
View directory record Official record
Conditions
Neoplasms
Interventions
NM-3
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

A Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573 in Subjects With Advanced Solid Tumors

NCT00816361
View directory record Official record
Conditions
Cancer
Interventions
MEDI-573
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

UCN-01 in Treating Patients With Advanced Cancer

NCT00003289
View directory record Official record
Conditions
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
7-hydroxystaurosporine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

NCT00741260
View directory record Official record
Conditions
Breast Cancer
Interventions
Neratinib, Capecitabine
Drug
Lead sponsor
Puma Biotechnology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
12
States / cities
Mobile, Alabama • Long Beach, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 2 Interventional

Screening Study for Participants With Malignant Tumors

NCT05419375
View directory record Official record
Conditions
Solid Tumors
Interventions
Screening platform
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
5
States / cities
Knoxville, Tennessee • Austin, Texas • Tyler, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Study of Continuous OSI-906 Dosing

NCT00514007
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 28, 2026, 2:55 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

NCT04439292
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions
Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors

NCT00281944
View directory record Official record
Conditions
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
oxaliplatin, fluorouracil, leucovorin calcium, pharmacological study, positron emission tomography, computed tomography
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2013 · Synced Oct 28, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

NCT06568614
View directory record Official record
Conditions
Advanced or Metastatic MTAP-deleted Solid Tumors
Interventions
BG-89894
Drug
Lead sponsor
BeOne Medicines
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

NCT01226316
View directory record Official record
Conditions
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, Tumour Response, Advanced or Metastatic Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, PIK3CA, AKT1, PTEN, ER Positive, HER2 Positive
Interventions
AZD5363
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • West Hollywood, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 28, 2026, 2:55 AM EDT
Recruiting Phase 1 Interventional

Trial of DFP-14927 in Advanced Solid Tumors

NCT03943004
View directory record Official record
Conditions
Solid Tumor, Cancer
Interventions
DFP-14927
Drug
Lead sponsor
Delta-Fly Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors

NCT01151384
View directory record Official record
Conditions
Solid Tumors
Interventions
LE-DT
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 28, 2026, 2:55 AM EDT
Recruiting Phase 1 Interventional

A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)

NCT06431594
View directory record Official record
Conditions
Solid Tumors, Neoplasms
Interventions
Mocertatug rezetecan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
18
States / cities
Birmingham, Alabama • Fountain Valley, California • Santa Rosa, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

HDCRT Plus Pembrolizumab in Advanced Malignancies

NCT02987166
View directory record Official record
Conditions
Solid Tumor
Interventions
High-Dose Conformal Radiation Therapy, Pembrolizumab
Radiation · Drug
Lead sponsor
James Larner, MD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Study of Nesvacumab (REGN910/ SAR307746)

NCT01271972
View directory record Official record
Conditions
Solid Tumors
Interventions
nesvacumab (REGN910/ SAR307746)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
San Francisco, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery

NCT01276496
View directory record Official record
Conditions
Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Cilengitide, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

Safety of PDT-Photofrin® Prior to Lung Surgery

NCT03344861
View directory record Official record
Conditions
Lung Cancer, Lung Cancer Metastatic
Interventions
Porfimer Sodium, Fiber optic
Drug · Device
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Denver, Colorado • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 28, 2026, 2:55 AM EDT
Terminated Phase 1 Interventional

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

NCT03783403
View directory record Official record
Conditions
Neoplasms
Interventions
CC-95251, Rituximab, Cetuximab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Phase I Study of Vorinostat and Sorafenib in Advanced Cancer

NCT00635791
View directory record Official record
Conditions
Malignant Solid Tumour, Renal Cell Carcinoma, Non Small Cell Lung Carcinoma
Interventions
Sorafenib, Vorinostat
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors

NCT02488759
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, Daratumumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional Results available

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas

NCT02171260
View directory record Official record
Conditions
Pediatrics, Solid Tumors
Interventions
Eribulin Mesylate
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 28, 2026, 2:55 AM EDT
Completed Phase 1 Interventional

Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)

NCT01957280
View directory record Official record
Conditions
Solid Tumors
Interventions
patritumab
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Tampa, Florida • Oklahoma City, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 28, 2026, 2:55 AM EDT